OncoTherapy Science, Inc.
4564.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥230 | ¥201 | ¥187 | ¥338 |
| % Growth | 14.4% | 7.9% | -44.7% | – |
| Cost of Goods Sold | ¥198 | ¥205 | ¥176 | ¥298 |
| Gross Profit | ¥33 | -¥4 | ¥11 | ¥40 |
| % Margin | 14.1% | -1.8% | 5.9% | 12% |
| R&D Expenses | ¥104 | ¥183 | ¥129 | ¥100 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥100 | ¥118 | -¥18 | ¥108 |
| Sales & Mktg Exp. | ¥0 | ¥0 | -¥34 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥18 | -¥100 |
| Operating Expenses | ¥205 | ¥300 | ¥129 | ¥108 |
| Operating Income | -¥172 | -¥304 | -¥118 | -¥167 |
| % Margin | -74.7% | -150.8% | -63.1% | -49.4% |
| Other Income/Exp. Net | -¥68 | -¥10 | ¥20 | -¥5 |
| Pre-Tax Income | -¥240 | -¥314 | -¥98 | -¥172 |
| Tax Expense | ¥1 | ¥1 | ¥1 | ¥0 |
| Net Income | -¥241 | -¥314 | -¥98 | -¥172 |
| % Margin | -104.5% | -156% | -52.5% | -50.9% |
| EPS | -0.76 | -1.13 | -0.36 | -0.63 |
| % Growth | 32.7% | -213.9% | 42.9% | – |
| EPS Diluted | -0.76 | -1.13 | -0.36 | -0.63 |
| Weighted Avg Shares Out | 319 | 278 | 271 | 272 |
| Weighted Avg Shares Out Dil | 319 | 278 | 271 | 272 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥0 | ¥0 | ¥0 | ¥167 |
| EBITDA | -¥240 | -¥313 | -¥115 | -¥171 |
| % Margin | -104.1% | -155.6% | -61.7% | -50.5% |